Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390)

Cancer

Volumn 82, Issue 11, 1998, Pages 2270-2274

  Forastiere, Arlene A ^a   Shank, Darleen ^b   Neuberg, Donna ^b   Taylor IV, Samuel G ^c   DeConti, Ronald C ^d,f   Adams, George ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Head and neck carcinoma; Paclitaxel; Response

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; LIVER TOXICITY; MALE; MAXIMUM PERMISSIBLE DOSE; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0032102421     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q     Document Type: Article

References (9)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-7.
2. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemia cell lines treated with Taxol. Cancer Res 1988;48:4093-160.
3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-9.
4. Forastiere AA, Neuberg D, Taylor SG IV, Ensley JF, Hutchins LF, Truozzi P. Phase II evaluation of taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group Trial. Monogr Natl Cancer Inst 1993;15:181-4.
5. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LA, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
6. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
7. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:521-6.
8. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995;22:41-6.
9. Loffler TM, Freund W, Lipke J, Hausamen TU. Schedule and dose intensified paclitaxel as weekly 1-hour infusion. Evidence for an improved toxicity profile and response activity in pretreated solid tumors. Proc Am Soc Clin Oncol 1995;14:470.